Yin G Wang

US Patent:

7823154, Oct 26, 2010

Filed:

Sep 16, 2005

Appl. No.:

11/228901

Inventors:

Yin Wang - Ann Arbor MI, US
Arif Merchant - Los Altos CA, US

Assignee:

Hewlett-Packard Development Company, L.P. - Houston TX

International Classification:

G06F 9/46
H04L 12/28
G06F 15/173

US Classification:

718102, 3703954, 709226

Abstract:

One embodiment of the present invention provides a method comprising assigning a first weight to a first consumer and a second weight to a second consumer. The method further comprises receiving at a first scheduler a request for service by a first resource to the first consumer; receiving at a second scheduler a request for service by a second resource to the first consumer; and receiving at the first scheduler a request for service by the first resource to the second consumer. The method further comprises scheduling, by the first and second schedulers, service from the first and second resources to the first and second consumers, wherein the scheduling maintains total service provided by the first and second resources to the first and second consumers in proportion to the respective weights of the first and second consumers without requiring the first and second schedulers to communicate with each other.

US Patent:

8158596, Apr 17, 2012

Filed:

May 12, 2008

Appl. No.:

12/119158

Inventors:

Yang Liu - Ann Arbor MI, US
Pan Zheng - Ann Arbor MI, US
Xing Chang - Ann Arbor MI, US
Lizhong Wang - Ann Arbor MI, US
Runhua Liu - Ann Arbor MI, US
Yin Wang - Ann Arbor MI, US
Yan Liu - Ann Arbor MI, US
Tao Zuo - Columbus OH, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 48/00
A01N 63/00

US Classification:

514 44R, 424 931

Abstract:

Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.

US Patent:

20110126219, May 26, 2011

Filed:

Nov 20, 2009

Appl. No.:

12/622737

Inventors:

Aameek Singh - University Place, IN
Sandeep M. Uttamchandani - San Jose CA, US
Yin Wang - Ann Arbor MI, US

Assignee:

INTERNATIONAL BUSINESS MACHINES CORPORATION - Armonk NY

International Classification:

G06F 9/46

US Classification:

719328

Abstract:

Management of a planner through use of a middleware layer. A computer system is configured with the middleware layer in communication with both a planner and a data repository. One or more modules are provided in the middleware layer to support the functionality of the planner. Application program interface calls are employed to call the modules, thereby mitigating duplication of the functionality in separate planners.

US Patent:

20120264697, Oct 18, 2012

Filed:

Jun 25, 2010

Appl. No.:

13/513659

Inventors:

Yang Liu - Ann Arbor MI, US
Yin Wang - Ann Arbor MI, US
Yan Liu - Ann Arbor MI, US
Sami N. Malek - Ann Arbor MI, US
Pan Zheng - Ann Arbor MI, US

Assignee:

ONCOIMMUNE INC. - Ann Arbor MI

International Classification:

A61K 38/12
A61P 35/00

US Classification:

514 196, 514 199

Abstract:

The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.